Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1/Phase 2

MTOR Inhibitors in Older Adults

University of Texas Southwestern Medical Center · with University of Maryland, Baltimore, National Institute on Aging (NIA) · NCT06727305

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 65–80 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1, Phase 2
Target enrollment
60
US sites recruiting
1
Study start
May 11, 2026
Record last updated
June 25, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy lifespan, a major challenge in developing clinical trials to establish the clinical efficacy of mTOR inhibitors is the absence of pharmacokinetics (PK) and pharmacodynamics (PD) data in older adults. The proposed study will provide the foundation for future clinical trials assessing the role of mTOR inhibitors on aging related indications

Being studied: Sirolimus 0.5 Mg Oral Tablet; Sirolimus 1Mg Oral Tablet; Sirolimus 2 MG Oral Tablet; Everolimus 0.5 MG Oral Tablet; Everolimus 1 MG Oral Tablet; Everolimus 2 MG Oral Tablet

Conditions: Aging

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Community-dwelling adults
  • Patients should be 65 Years and older
  • Patients is able to understand and follow trial procedures

Exclusion Criteria

  • Creatinine clearance \<30 mL/min;
  • History of chronic liver disease;
  • Uncontrolled Hypertension (i.e., systolic blood pressure >160 mm Hg);
  • Hemorrhagic central nervous system (CNS) event within 1 year from screening visit;
  • Thrombotic event (DVT,PE) within 1 year from screening visit if not on anticoagulation;
  • Planned major surgical procedures;
  • Cardiovascular diseases ( i.e., admission for heart failure or myocardial infarction within 12 months);
  • Taking medication that increase or decrease sirolimus blood concentrations;
  • Other investigational therapy received within 1 month prior to screening visit;
  • History of dementia; 11 Dependence in any Katz Basic Activities of Daily Living.

Recruiting US locations

  • UT Southwestern Medical Center

    Dallas, TX 75390

    Site contact: Rhoda Annoh Gordon, PharmD, MPH · 2146457108 · Rhoda.annohgordon@utsouthwestern.edu

Study contacts (from the official record)

  • Irina Timofte, MD, MS · 2163347534 · Irina.Timofte@utsouthwestern.edu
All healthy volunteers studies in Texas →
MTOR Inhibitors in Older Adults (NCT06727305) | Bored Studies